Novo Nordisk A/S (NVO)

NYSE: NVO · IEX Real-Time Price · USD
96.32
-3.24 (-3.25%)
At close: Jan 14, 2022 4:00 PM
96.33
0.01 (0.01%)
After-hours:Jan 14, 2022 7:52 PM EST
Market Cap219.45B
Revenue (ttm)21.03B
Net Income (ttm)7.22B
Shares Out2.28B
EPS (ttm)3.08
PE Ratio31.32
Forward PE34.36
Dividend$1.31 (1.36%)
Ex-Dividend DateAug 16, 2021
Volume2,463,889
Open97.05
Previous Close99.56
Day's Range95.36 - 98.10
52-Week Range66.59 - 117.35
Beta0.26
AnalystsHold
Price Target108.16 (+12.3%)
Earnings DateNov 5, 2021

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a...

IndustryPharmaceuticals
Founded1923
CEOLars Fruergaard Joergensen
Employees46,982
Stock ExchangeNYSE
Ticker SymbolNVO
Full Company Profile

Financial Performance

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for Novo Nordisk stock is "Hold." The 12-month stock price forecast is 108.16, which is an increase of 12.29% from the latest price.

Price Target
$108.16
(12.29% upside)
Analyst Consensus: Hold

News

Novo Nordisk announces settlement of securities lawsuit in Denmark

Bagsværd , De n mark, 14 January 202 2 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability...

2 days ago - GlobeNewsWire

FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report

Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug ...

2 days ago - Benzinga

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 10 January 202 2 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Counci...

6 days ago - GlobeNewsWire

These 5 Stocks Moved the Market in 2021

These were the most important forces driving the stock market last year.

Other symbols:GOOGGOOGLHDNVDAWFC
3 weeks ago - The Motley Fool

Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades

Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had temporarily halted deliveries and manufacturing after issues relating to good ...

3 weeks ago - Benzinga

Novo Nordisk shares slump on U.S. supply challenges for obesity drug

Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.

3 weeks ago - Reuters

Final Trades: WRK, NVO, LULU & TGT

The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Steve Grasso, Jeff Mills and Nadine Terman.

Other symbols:LULUTGTWRK
4 weeks ago - CNBC Television

Novo Nordisk announces supply challenges for Wegovy® in the US

Bagsværd , De n mark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy ® pens for the US market has temporarily stopped deliveries and manufacturi...

4 weeks ago - GlobeNewsWire

DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of P...

NEW ORLEANS, Dec. 14, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

1 month ago - PRNewsWire

Digital Behavioral Health Innovator Ksana Health Joins Novo Nordisk's Global Prevention Accelerator

EUGENE, Ore.--(BUSINESS WIRE)-- #BehavioralHealth--Ksana Health, a digital behavioral health company, today announced its selection by Novo Nordisk's Global Prevention Accelerator.

1 month ago - Business Wire

Novo Nordisk A/S: Share repurchase programme

Bagsværd , Denmark, 6 December 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Counci...

1 month ago - GlobeNewsWire

Final Trades: NVO, TSE, WMT & bitcoin

The traders offer their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Steve Grasso, Brian Kelly and Nadine Terman.

Other symbols:TSEWMT
1 month ago - CNBC Television

Novo Nordisk announces impact from Volume Based Procurement for insulin in China

Bagsværd , De n mark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National ...

1 month ago - GlobeNewsWire

Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

Other symbols:DRNA
1 month ago - Zacks Investment Research

Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%

Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 b...

Other symbols:DRNA
1 month ago - Invezz

Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dice...

Other symbols:DRNA
1 month ago - Benzinga

Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion

(Reuters) -Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.

Other symbols:DRNA
1 month ago - Reuters

Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals

Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.

Other symbols:DRNA
1 month ago - Market Watch

3 Big Pharma Outperformers to Watch Out For in the Near Term

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Other symbols:LLYPFE
1 month ago - Zacks Investment Research

Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy

The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.

2 months ago - Zacks Investment Research

EMA Backs Approval Of Novo Nordisk's Ozempic 2mg Dose For Diabetes

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for Novo Nordisk A/S's (NYSE: NVO) Ozempic's new...

2 months ago - Benzinga

Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

Bagsværd, Denmark, 8 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accorda...

2 months ago - GlobeNewsWire

Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase pr...

Bagsværd , Denmark, 5 November 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 4,109 million from Novo Holdings A/S. This transa...

2 months ago - GlobeNewsWire

Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2021

Bagsværd, Denmark, 4 November 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso...

2 months ago - GlobeNewsWire

Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.

2 months ago - Zacks Investment Research